JP5367377B2 - 炎症性疾患治療のためのランチオニン関連化合物 - Google Patents

炎症性疾患治療のためのランチオニン関連化合物 Download PDF

Info

Publication number
JP5367377B2
JP5367377B2 JP2008549685A JP2008549685A JP5367377B2 JP 5367377 B2 JP5367377 B2 JP 5367377B2 JP 2008549685 A JP2008549685 A JP 2008549685A JP 2008549685 A JP2008549685 A JP 2008549685A JP 5367377 B2 JP5367377 B2 JP 5367377B2
Authority
JP
Japan
Prior art keywords
cancer
heteroatom
lanthionine
disease
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2008549685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009522377A (ja
JP2009522377A5 (enExample
Inventor
ケネス ヘンズリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of JP2009522377A publication Critical patent/JP2009522377A/ja
Publication of JP2009522377A5 publication Critical patent/JP2009522377A5/ja
Application granted granted Critical
Publication of JP5367377B2 publication Critical patent/JP5367377B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2008549685A 2006-01-09 2007-01-09 炎症性疾患治療のためのランチオニン関連化合物 Expired - Fee Related JP5367377B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US75725206P 2006-01-09 2006-01-09
US60/757,252 2006-01-09
US78179406P 2006-03-13 2006-03-13
US60/781,794 2006-03-13
US80414906P 2006-06-07 2006-06-07
US60/804,149 2006-06-07
PCT/US2007/060277 WO2007082208A2 (en) 2006-01-09 2007-01-09 Lanthionine-related compounds for the treatment of inflammatory diseases

Publications (3)

Publication Number Publication Date
JP2009522377A JP2009522377A (ja) 2009-06-11
JP2009522377A5 JP2009522377A5 (enExample) 2010-02-25
JP5367377B2 true JP5367377B2 (ja) 2013-12-11

Family

ID=38051848

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008549685A Expired - Fee Related JP5367377B2 (ja) 2006-01-09 2007-01-09 炎症性疾患治療のためのランチオニン関連化合物

Country Status (10)

Country Link
US (1) US7683055B2 (enExample)
EP (1) EP1981862B1 (enExample)
JP (1) JP5367377B2 (enExample)
AT (1) ATE500236T1 (enExample)
AU (1) AU2007204757B2 (enExample)
CA (1) CA2636042C (enExample)
DE (1) DE602007012833D1 (enExample)
DK (1) DK1981862T3 (enExample)
PT (1) PT1981862E (enExample)
WO (1) WO2007082208A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141497A (ja) * 2016-02-12 2017-08-17 二村　芳弘 エラスチン増加作用を呈するメチルランチオニン誘導体の製造方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2305834A1 (en) * 2009-10-02 2011-04-06 Advanced Practical Diagnostics N.V. Haplotype of KATIII gene
EP2524925B1 (en) * 2009-12-28 2016-08-17 Ajinomoto Co., Inc. Lanthionine derivative
WO2011140215A2 (en) * 2010-05-04 2011-11-10 Virginia Tech Intellectual Properties, Inc. Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders
WO2012027455A1 (en) * 2010-08-24 2012-03-01 The University Of Toledo Glutathione-lanthionine compounds and methods related thereto
CN102670796A (zh) * 2012-05-22 2012-09-19 广西天天乐药业股份有限公司 一种治疗脾胃虚弱的中药及其制备方法
US11084836B2 (en) * 2016-02-26 2021-08-10 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same
US10882831B2 (en) * 2017-02-23 2021-01-05 The University Of Toledo Compositions useful in therapy of autophagy-related pathologies, and methods of making and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2283186A (en) * 1942-05-19 Thiazane-j
US6025395A (en) * 1994-04-15 2000-02-15 Duke University Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders
MXPA03006321A (es) * 2001-01-16 2003-10-06 Genset Sa Tratamiento de trastornos del sistema nervioso central usando antagonistas de d-aminoacido oxidasa y d-aspartato oxidasa.
US20030166554A1 (en) * 2001-01-16 2003-09-04 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists
US20030185754A1 (en) * 2001-01-16 2003-10-02 Genset, S.A. Treatment of CNS disorders using D-amino acid oxidase and D-aspartate oxidase antagonists

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017141497A (ja) * 2016-02-12 2017-08-17 二村　芳弘 エラスチン増加作用を呈するメチルランチオニン誘導体の製造方法

Also Published As

Publication number Publication date
EP1981862B1 (en) 2011-03-02
US7683055B2 (en) 2010-03-23
DE602007012833D1 (de) 2011-04-14
DK1981862T3 (da) 2011-06-14
JP2009522377A (ja) 2009-06-11
EP1981862A2 (en) 2008-10-22
ATE500236T1 (de) 2011-03-15
AU2007204757B2 (en) 2012-09-06
US20070197515A1 (en) 2007-08-23
WO2007082208A3 (en) 2007-09-13
CA2636042C (en) 2014-10-14
WO2007082208A2 (en) 2007-07-19
AU2007204757A1 (en) 2007-07-19
PT1981862E (pt) 2011-06-01
CA2636042A1 (en) 2007-07-19

Similar Documents

Publication Publication Date Title
JP5367377B2 (ja) 炎症性疾患治療のためのランチオニン関連化合物
JP7262118B2 (ja) 医薬組成物およびその使用
JP6867652B2 (ja) 癌療法のためのモノマレイミド官能化白金化合物
JP2022095882A (ja) 神経膠腫を含むがんを処置するためのエフロルニチンおよびその誘導体および類似体の組成物ならびにそれらの使用方法
JP2013512966A (ja) 眼疾患を治療する化合物および方法
CN106999540A (zh) 组合疗法
US20250367229A1 (en) Treatment of Immune-Related Disorders, Kidney Disorders, Liver Disorders, Hemolytic Disorders, and Oxidative Stress-Associated Disorders Using NRH, NARH and Reduced Derivatives Thereof
WO2017004485A1 (en) Ado-resistant cysteamine analogs and uses thereof
CN114599371A (zh) 作为癌症靶向药物载体的磷脂醚缀合物
JP2009535410A (ja) ピロロキノリンキノンおよびその使用
JP2022533697A (ja) Ｇａｐｄｈを阻害する方法及び組成物
CN118946371A (zh) 靶向psma的放射性药物和检查点抑制剂的组合疗法
AU2012387970B2 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof
AU2017235350B2 (en) Combination therapy for proliferative diseases
KR20230136627A (ko) 포유 동물에서 체중 감소를 유도하기 위한 외인성 케톤 에스테르의 용도
US20130209366A1 (en) Glutathione-Lanthionine Compounds and Methods Related Thereto
US11136295B2 (en) D-amphetamine compounds, compositions, and processes for making and using the same
JP6429399B2 (ja) 抗プリオン化合物のマレイン酸塩及びその製造方法、並びにその医薬組成物
JP2007538080A (ja) α−ケト分岐鎖アミノ酸を用いた脳神経細胞内グルタミン酸レベルの低減
WO2006014507A2 (en) Method for inhibiting lipid peroxidation
WO2024156704A1 (en) Novel mixtures as ras inhibitors for use in the treatment of proliferative and genetic diseases
NZ703195B2 (en) Pharmaceutical composition for inhibiting autophagy of motor neurons and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100108

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100108

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121218

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130815

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130911

R150 Certificate of patent or registration of utility model

Ref document number: 5367377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees